Low-dose drugs with standard local treatment for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests giving a low dose of two drugs (bevacizumab and atezolizumab) alongside standard local treatments (TACE and HAIC) for liver cancer that cannot be removed with surgery. The goal is to see if this combination helps control the tumor better or improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have liver cancer (hepatocellular carcinoma) that cannot be surgically removed.
- The cancer is suitable for a treatment called TACE (chemoembolization) and HAIC (hepatic artery infusion chemotherapy).
- You have not had any prior whole-body treatment for liver cancer.
- Your health status is good (ECOG 0 or 1) and your liver function is at least mildly preserved (Child-Pugh class A or B7).
- You do not have serious autoimmune disease, active infections, or recent heart or blood vessel problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a combination of immune therapy (atezolizumab) and a blood-vessel-targeting drug (bevacizumab) works better than a standard procedure called TACE for people with intermediate-stage liver cancer (HCC). It may help shrink tumors and help patients live longer with fewer complications.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. It uses a procedure to block the tumor's blood supply plus two drugs that help the immune system fight the cancer. This may help shrink tumors and slow the disease.
This Phase 2 trial tests whether atezolizumab plus bevacizumab, given along with liver cancer treatment procedures (TACE/HAIC), can help people with advanced liver cancer that cannot be removed by surgery. It mainly looks at whether these medicines can control the cancer more effectively and safely.
This trial tests if combining two immunotherapy drugs (atezolizumab and bevacizumab) with a brain-health medicine (memantine) can help people with advanced liver cancer that isn't treatable with surgery. It aims to see if this triple therapy works better than standard options.
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.